VICTORIS
Budget Express 2026

co-presented by

  • LIC
  • JIO BlackRock

ASSOCIATE SPONSORS

  • Sunteck
  • SBI
  • Emirates
  • Dezerv
HomeNewsOnline pharmacy

Online Pharmacy

Jump to
  • PharmEasy raises $216 million at a 90% lower valuation from peak

    The online pharmacy was last valued at $5.6 billion in 2021, followed by nearly 90 percent decrease in its valuation amidst debt repayment related challenges.

  • Lupin to sell generic respiratory drugs on Mark Cuban's online pharmacy

    The partnership with Cuban-backed Cost Plus Drugs is expected to bolster Lupin's U.S. business, which already accounts for nearly 33% of its 2023 revenue.

  • Pharmeasy to seek funding from Manipal only in case of shortfall in rights issue

    The Manipal Group's family office had made a binding offer to invest up to Rs 1,300 crore in the online pharmacy

  • E-pharmacies ready to engage with Centre for regulation: Prashant Tondon of TATA1mg

    In a wideranging interview, the CEO of India’s biggest e-pharmacy defended online retailers, saying they are in full compliance with the law.

  • Why DCGI served a show-cause notice on e-pharmacies

    Online pharmacies do not comply with licence conditions like selling against a prescription, maintaining records about the sale of Schedule H drugs, and more, which can lead to drug abuse and self-medication.

  • Tata1mg focusing on expansion in Tier 3 cities, working to reduce delivery time; says CTO Gaurav Agarwal

    The co-founder of the online pharmaceutical retailer wants the Centre to spell out clear guidelines on predatory pricing and heavy discounts on drugs being offered by some e-pharmacies.

  • PharmEasy FY22 loss widens to Rs 2,700 cr as employee costs surge five-fold

    Pharmeasy reported a net loss of Rs 3,992 crore for FY22 against Rs 641 crore in FY21 (2020-21), the company's filings with the Ministry of Corporate Affairs showed. However, excluding exceptional items or one-time loss on impairment of goodwill, the company reported a loss of Rs 2,731 crore during the year, the filings showed.

  • Flipkart now sells medicines online through Health+ app

    Customers, both caregivers and patients, will now be able to order more than 48,000 prescription medicines via the Flipkart app

  • Tata 1mg FY22 revenue up 66% to Rs 222 crore; net loss narrows to Rs 146 crore

    Tata 1mg's revenue from operations in FY21 stood at Rs 134.04 crore and its net loss was Rs 281.41 crore. Its other income for the financial year ended March 31, 2021, was Rs 24.14 crore.

  • Apollo pharmacy products will soon be available on Amazon

    Online pharmacy is becoming a fiercely competitive space as Reliance recently bought NetMeds and Tata Digital acquired 1mg. Amazon's partnership with an offline large player will heat up the space even more.

  • Online pharmacy 1mg to start subscription model soon

    Subscription model is expected to go a long way in improving the order predictability of e-commerce companies, especially e-pharmacy segment, which specially is, marred with high cancellation rates.

  • Netmeds closes $50 mn funding led by OrbiMed

    Netmeds founder Pradeep Dadha's family investment fund, boutique investment bank MAPE Advisory Group also participated in the funding, the company said in a statement.

  • mChemist Global Pvt. Ltd. Launches India`s First True Online Pharmacy, mChemist.com

    For middle age and elderly patients, ‘mail order service’ for chronic medicines has been a boon in developed countries. Patients, payers ...

  • Alibaba Health shares to open up 77% on e-pharma biz merger

    Alibaba Group's effective equity ownership of Alibaba Health will increase from 38 percent to about 53 percent, making it a consolidated subsidiary of the group, China's biggest e-commerce company said.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347